Skip to main content
Home

Main navigation

  • Home
  • News
  • About HIV
  • About us
  • Donate
Search
Donate now

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you.

I am a UK taxpayer and I understand that if I pay less Income and /or Capital Gains Tax than the amount of Gift Aid claimed on all my donations in the relevant tax year, it is my responsibility to pay any difference.

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing life-changing information. Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness.

  • £5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment.
  • £10 helps us produce news and bulletins on the latest developments in HIV for healthcare staff around the world.
  • £35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts.
Conferences

IDWeek 2013

The IDWeek 2013 conference was held in San Francisco, USA, 2-6 October 2013.
Improving HIV care

Studies look at community vs hospital-based HIV care and medication issues

7 October 2013
Testing & health monitoring

HIV monitoring every six months is adequate for people on ART with stable viral suppression

10 October 2013
Bone & joint problems

HIV-positive people not on antiretrovirals are prone to inflammation-related bone loss

16 October 2013
Vaccinations & immunisations

HIV-positive young women have adequate response to human papillomavirus vaccine

16 October 2013
New & experimental hepatitis C treatment

Predicting response to acute hepatitis C treatment in HIV/HCV co-infected people

14 October 2013
Starting treatment

Eviplera works well regardless of viral load or CD4 count, may improve lipid levels

11 October 2013
New & experimental hepatitis C treatment

Daclatasvir works well against hepatitis C either with interferon or in all-oral regimen

10 October 2013
Cardiovascular disease

People with HIV have higher risk of death after heart attack

8 October 2013
Side effects

Does efavirenz use raise the risk of suicide in people with HIV?

8 October 2013
Treatment outcomes & life expectancy

Liver fibrosis linked to immune activation in HIV/HCV co-infected women

7 October 2013
Injectable & long-acting HIV treatment

Long-acting antiretrovirals may improve survival for people with poor adherence

4 October 2013
Sign up for our email bulletins.
Sign up

Editors’ picks from other sources

New & experimental hepatitis C treatment

Interferon-free therapy alters lipid metabolism, glucose homeostasis in chronic HCV patients

Patients with chronic hepatitis C treated with an interferon-free regimen consisting of sofosbuvir and ribavirin experienced changes in LDL, triglycerides, hemoglobin A1C and metabolic and hepatic lipid gene expression in a study presented at ID Week 2013.
Healio Hepatology
14 Oct 13
TB treatment

IDWeek: Latest approach to TB treatment looks at novel drug regimens

With the pipeline for new tuberculosis drugs “perilously under populated,” the new paradigm in tuberculosis treatment focuses on using existing drugs and evaluating them in combination to develop better, shorter regimens, according to leading physician scientists at last week’s IDWeek meeting in San Francisco. Researchers are now looking at individual drug compounds and putting them together in novel ways to treat the disease that claims more than a million lives every year.
Science Speaks
12 Oct 13
HIV treatment

News from IDWeek 2013

Several thousand researchers, clinicians, public health officials, and others converged in San Francisco last week for IDWeek 2013, a combined conference of the Infectious Diseases Society of America, the HIV Medicine Association, the Society for Healthcare Epidemiology of America, and the Pediatric Infectious Diseases Society.
BETA
11 Oct 13
PrEP

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

Once-a-month HIV antiretroviral dosing is no longer a fanciful dream. Long-acting antiretrovirals are currently in development, and the first glimpses of early safety/efficacy data are not terribly far away. So it's not outlandish for us to start thinking about where these drugs might fit into the HIV treatment armamentarium once they arrive. But will they be cost-effective?
The Body Pro
6 Oct 13
More editors' picks

About us

Our information is intended to support, rather than replace, consultation with a healthcare professional.

Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

Connect with us

  • Twitter
  • Facebook
  • YouTube
  • Instagram

Links

Show — Links Hide — Links
  • Contact us
  • THT Direct Helpline
  • Subscribe to email bulletins

 

aidsmap (previously known as NAM aidsmap) is now hosted by Terrence Higgins Trust, an HIV charity based in the United Kingdom.

 

Copyright 2025 © Terrence Higgins Trust is a registered charity in England and Wales (reg. no. 288527) Company reg. no. 1778149 and a registered charity in Scotland (reg. no. SC039986). Registered office: 437 & 439 Caledonian Road, London, N7 9BG.

Footer menu

Show — Footer menu Hide — Footer menu
  • Accessibility
  • Compliment, complaint or concern
  • Our information
  • Privacy & cookies
  • Terms of use
  • Terrence Higgins Trust